KDMN Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 saus. 1970 @ 03:00):

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases...

Stats
Dzisiejszy wolumen	10.42M
Średni wolumen	10.03M
Kapitalizacja rynkowa	0.00
EPS	$-0.200 ( 2021-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.32
ATR14	$0.213 (2.24%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-09	Waksal Harlan	Sell	177 945	Common Stock
2021-11-09	Waksal Harlan	Buy	655 000	Stock Appreciation Right
2021-11-09	Waksal Harlan	Buy	982 500	Performance Stock Option(right to buy)
2021-11-09	Waksal Harlan	Buy	1 350 000	Stock Option (right to buy)
2021-11-09	Waksal Harlan	Buy	2 000 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 93 transactions
Buy: 16 325 233 \| Sell: 4 159 124

Wolumen Korelacja

Długi: 0.23 (neutral)

Krótki: 0.86 (strong)

Signal:(72.9) Same movement expected

Kadmon Holdings Inc Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kadmon Holdings Inc Korelacja - Waluta/Towar

0.83
( strong )

0.90
( very strong )

-0.86
( strong negative )

0.80
( moderate )

-0.57
( weak negative )

Kadmon Holdings Inc Finanse

Annual	2020
Przychody:	$8.29M
Zysk brutto:	$6.29M (75.86 %)
EPS:	$-0.670

FY	2020
Przychody:	$8.29M
Zysk brutto:	$6.29M (75.86 %)
EPS:	$-0.670

FY	2019
Przychody:	$5.10M
Zysk brutto:	$3.81M (74.70 %)
EPS:	$-0.480

FY	2018
Przychody:	$1.40M
Zysk brutto:	$714 000 (51.15 %)
EPS:	$-0.580

Financial Reports:

No articles found.

Kadmon Holdings Inc

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.